Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 725 clinical trials
Featured trial
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable

bladder cancer
urothelial carcinoma
metastatic urothelial carcinoma
bladder carcinoma
  • 259 views
  • 10 May, 2022
  • 64 locations
Featured trial
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

>Objective: To test how safe and effective a combination of ibrutinib, short-course fludarabine, and pembrolizumab is for people with chronic lymphocytic leukemia (CLL), also known as

ibrutinib
neutrophil count
night sweats
chronic lymphocytic leukemia
fludarabine
  • 359 views
  • 23 Nov, 2020
  • 1 location
Featured trial
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma

Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma

  • 831 views
  • 23 Nov, 2020
  • 5 locations
Featured trial
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Patients With Follicular Non-Hodgkin’s Lymphoma

intratumorally at the maximum safe dose determined in Part 1 following local radiation or will receive the same treatment regimen sequentially administered with pembrolizumab. A second treatment group may be

lymphoma
non-hodgkin's lymphoma
lymphomas
  • 286 views
  • 22 Dec, 2020
  • 31 locations
Featured trial
Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-7)

This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS

KRAS
pembrolizumab
  • 36 views
  • 29 Sep, 2022
  • 98 locations
Featured trial
Study of HB-200 alone and with pembrolizumab for patients with Recurrent/ Metastatic HPV 16+ Head and Neck and other Cancers

pembrolizumab as part of their standard of care.This trial also enrolls patients who have HPV 16+ head and neck cancers who have received prior therapy in metastatic/recurrent setting (2L+). Patients

cancer
measurable disease
squamous cell carcinoma
carcinoma
pembrolizumab
  • 0 views
  • 27 May, 2022
  • 16 locations
Featured trial
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

  • 140 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma

A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of

  • 222 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

advanced solid tumor
solid tumor
malignant solid tumor
  • 538 views
  • 22 Nov, 2021
  • 62 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). There will

prednisone
docetaxel
solid tumour
gonadotropin releasing hormone
enzalutamide
  • 3 views
  • 04 Oct, 2022
  • 32 locations